Clinical trial
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
NCT00073749 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00073749 |
|---|---|
| Title | Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma |
| Official title | A Phase 1 Study Of Cmc-544 Administered As A Single Agent In Subjects With B-cell Non- Hodgkin's Lymphoma |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, B-Cell |
| Intervention type | Drug |
| Interventions | Inotuzumab ozogamicin [CMC-544] |
| Enrollment | 79 |
| Start date | Aug 1, 2003 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Dec 5, 2003 |
| Last update posted | Dec 17, 2018 |
| Countries | Belgium, France, Germany, Spain, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: